188 related articles for article (PubMed ID: 9269683)
1. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
Stewart A
Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
[No Abstract] [Full Text] [Related]
2. Protein kinase C as a target for cancer therapy.
Glazer RI
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
[No Abstract] [Full Text] [Related]
3. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D; Lahn M
Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: ISIS-3521.
Li K; Zhang J; Sirois P; Hu Y
Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
[TBL] [Abstract][Full Text] [Related]
7. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
8. The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen.
Hanauske AR; Sundell K; Lahn M
Curr Pharm Des; 2004; 10(16):1923-36. PubMed ID: 15180529
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.
McGraw K; McKay R; Miraglia L; Boggs RT; Pribble JP; Muller M; Geiger T; Fabbro D; Dean NM
Anticancer Drug Des; 1997 Jul; 12(5):315-26. PubMed ID: 9236849
[No Abstract] [Full Text] [Related]
10. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
McKay RA; Miraglia LJ; Cummins LL; Owens SR; Sasmor H; Dean NM
J Biol Chem; 1999 Jan; 274(3):1715-22. PubMed ID: 9880552
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides in lung cancer.
Pujol JL; Jacot W
Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
[No Abstract] [Full Text] [Related]
12. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
[TBL] [Abstract][Full Text] [Related]
14. Antisense approaches for the treatment of cancer.
Monia BP; Holmlund J; Dorr FA
Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
[No Abstract] [Full Text] [Related]
15. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
Geiger T; Müller M; Dean NM; Fabbro D
Anticancer Drug Des; 1998 Jan; 13(1):35-45. PubMed ID: 9474241
[TBL] [Abstract][Full Text] [Related]
16. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
Holmlund JT
Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer.
Carter CA
Curr Drug Targets; 2000 Sep; 1(2):163-83. PubMed ID: 11465069
[TBL] [Abstract][Full Text] [Related]
18. Analysts: Isis-Lilly deal validates antisense.
Niiler E
Nat Biotechnol; 2001 Oct; 19(10):898-9. PubMed ID: 11581643
[No Abstract] [Full Text] [Related]
19. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
20. Antisense strategies targeting protein kinase C: preclinical and clinical development.
Tortora G; Ciardiello F
Semin Oncol; 2003 Aug; 30(4 Suppl 10):26-31. PubMed ID: 12917818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
